Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DN-101 + Docetaxel in AIPC (ASCENT-2)
NCT00273338Phase 3Terminated
- Sponsor
- Novacea
- Start
- Jan 2006
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of Asentar in prostate cancer (PCa) (2 arms), sponsored by Novacea. Primary endpoint: Overall Survival. Started Jan 2006; status: terminated.
02
Drugs
Asentar
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00273338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00273338.